

Michael T. Christensen, MD MBA

Board Certified Radiation Oncologist
Assistant Clinical Professor
Independent Medical Expert



CONTACT INFORMATION

Email **michaeltchristensen@gmail.com**
Phone **480-586-1338**
Location **Gilbert, Arizona**

BOARD CERTIFICATION & LICENSURE

American Board of Radiology **Radiation Oncology (Board Certified)**
Medical Licensure **Arizona (Active)**

AREAS OF EXPERTISE

- Oncology diagnosis, staging, treatment decision-making, and standard of care
- Evaluation of alleged misdiagnosis and delayed diagnosis
- Radiation oncology standard of care
- Radiation toxicities and complication management
- Advanced treatment planning (3D, IMRT, VMAT, SBRT, SRS)
- Gamma Knife and CyberKnife radiosurgery

WORK EXPERIENCE

05/2025 – Present	City of Hope Cancer Center Assistant Clinical Professor	Gilbert, AZ
08/2024 – 05/2025	Optum Cancer Care Radiation Oncology Centers of Nevada	Las Vegas, NV

EDUCATION & CLINICAL TRAINING

07/2020 – 6/2024	Radiation Oncology Residency University of Texas Southwestern Medical Center Chief Resident 2023	Dallas, TX
08/2022 – 08/2023	University of Texas at Dallas Master of Business Administration (MBA) Scholar with Distinction	Dallas, TX
07/2019 – 06/2020	Transitional Year Internship University of California, Riverside Riverside Community Hospital	Riverside, CA
08/2015 – 05/2019	University of Utah School of Medicine Doctor of Medicine (MD) Alpha Omega Alpha (AOA) Honor Society	Salt Lake City, UT
08/2009 – 04/2015	Brigham Young University Bachelor of Science (BS) in Neuroscience Magna Cum Laude	Provo, UT

HONORARY/PROFESSIONAL MEMBERSHIPS

2019 – present American Society for Radiation Oncology (ASTRO)
2018 – present Alpha Omega Alpha (AOA) Honor Society

SELECT PUBLICATIONS

1. **Christensen M.**, Kumar K., Wang W., Dharmarajan K., Chang Z., McStay C., Barina A., Siropaides C. Serious Illness Communication Training among Radiation Oncology Residents. *Practical Radiation Oncology*. 2022. <https://pubmed.ncbi.nlm.nih.gov/36526246/>
Podcast feature: <https://www.practicalradonc.org/audio-do/delivering-bad-news>

2. **Christensen M.**, Hannan R. Role of Primary and Metastasis-Directed Stereotactic Radiation Therapy for Advanced Renal Cell Carcinoma. *Sequencing Therapies in Advanced Renal Cell Carcinoma*. Springer. 2022. (In Press)
3. **Christensen M.**, Hannan R. The Emerging Role of Radiation Therapy in Renal Cell Carcinoma. *Cancers*, 14, 4693. 2022. <https://doi.org/10.3390/cancers14194693>
4. Hannan R., **Christensen M.**, et al. Stereotactic Ablative Radiation for Systemic Therapy Naïve Oligometastatic Kidney Cancer. *European Urology Oncology*. 2022. <https://pubmed.ncbi.nlm.nih.gov/35985982/>
5. Hannan R., **Christensen M.**, et al. Phase II Trial of Stereotactic Ablative Radiation for Oligoprogressive Metastatic Kidney Cancer. *European Urology Oncology*. 2021. <https://pubmed.ncbi.nlm.nih.gov/34986993/>
6. Ager B*, **Christensen M***, Burt L., Poppe M. The value of high-dose radiotherapy in intracranial ependymoma. *Pediatric Blood & Cancer*. 2019. <https://pubmed.ncbi.nlm.nih.gov/30865382/>
*Co-First Authors
7. Boothe D., Wolfson A., **Christensen M.**, Francis S., Werner T., Gaffney D. Lymphovascular invasion in endometrial cancer: prognostic value and implications on adjuvant radiation therapy use. *International Journal of Gynecological Cancer*. 2019. <https://pubmed.ncbi.nlm.nih.gov/31169554/>